<DOC>
	<DOCNO>NCT01601080</DOCNO>
	<brief_summary>This observational , retrospective , UK &amp; Ireland audit measure patient adherence Rebif® injection RebiSmart™ injection device . Data collect Multiple Sclerosis ( MS ) patient prescribe Rebif® use RebiSmart™ device injection minimum 24 month .</brief_summary>
	<brief_title>An Observational , Retrospective , UK &amp; Ireland Audit Patient Adherence Rebif® Injections Using RebiSmart™ Injection Device</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Relapsing Multiple Sclerosis ( Relapsing Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis relapse ) accord Association British Neurologists criterion ( 30 ) UK revise 2005 McDonald criterion ( 31 ) Ireland Prescribed Rebif® ( 22mcg 44mcg ) use RebiSmart™ injection device Have use RebiSmart™ 24 month due device replacement part standard routine care Registered Bupa Home Healthcare ( UK ) SENSE nurse ( Ireland ) Be willing give consent adherence data capture audit Patients fulfill entirely inclusion criterion well follow : Discontinued Rebif 24 month treatment Unable unwilling give consent adherence data capture audit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>